FDA says cancer medication may be linked to increased risk for second cancers.

Dow Jones Newswire (5/8, Dooren, Subscription Publication) reports that the FDA has announced that some individuals who received the cancer medication Revlimid (lenalidomide) may face a higher risk of developing certain new kinds of cancers. The agency said the information will now be included on the drug's label.